nejm semaglutide heart failure Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – SOUL Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 SELECT Trial

(The brand-name GLP-1s arent available as generics because the patents havent expiredNovo Nordisk has its US patent on semaglutide until 2032, and Eli Lilly on tirzepatide, until 2036.) But to be clear, compounders do still operate within a regulatory framework, albeit a less stringent one

Medical credit companies like CareCredit and Cherry allow you to spread costs over several months

Grabrucker AM (2013) Environmental factors in autism

A landmark trial in the New England Journal of Medicine found that patients maintaining GLP-1 therapy preserved 80% of their weight loss two years into treatment, while those who stopped regained most losses

A one-time shipment with no follow-up is not medical care